Polymer nanocarriers for the delivery of small fragments of nucleic acids: Oligonucleotides and siRNA

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 71, Issue 3, 2009, Pages 490-504

  de Martimprey, H ^a,b   Vauthier, C ^a   Malvy, C ^a,b   Couvreur, P ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Nanocapsules; Nanocarriers; Nanoparticles; ODN; Oligonucleotides; Polymer micelles; RNA interference; RNAi; siRNA

Indexed keywords

ALGINIC ACID; ANTISENSE OLIGONUCLEOTIDE; ARGINYLGLYCYLASPARTIC ACID; CETRIMIDE; CHITOSAN; GELATIN; NANOCAPSULE; NANOCARRIER; NUCLEIC ACID; POLOXAMER; POLY(ALKYL 2 CYANOACRYLATE); POLY(DIMETHYLAMINOETHYL METHACRYLATE); POLY(ISOBUTYL 2 CYANOACRYLATE); POLY(TRIMETHYLAMINOETHYL METHACRYLATE); POLYETHYLENEIMINE; POLYLYSINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTIANGIOGENIC GENE THERAPY; BIOLOGICAL ACTIVITY; BREAST CANCER; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL STRAIN L 929; CHEMICAL STRUCTURE; CHRONIC TOXICITY; COMPLEMENT ACTIVATION; EMBRYOTOXICITY; ENDOCYTOSIS; EWING SARCOMA; GENE SILENCING; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; MICELLE; NANOGEL; NANOTECHNOLOGY; NEUROBLASTOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUDE MOUSE; ONCOGENE H RAS; OVARY CARCINOMA; PRIMATE; RAT; REVIEW; RNA DEGRADATION; RNA INTERFERENCE; TERATOGENICITY; THYROID CARCINOMA; THYROID PAPILLARY CARCINOMA; TRANSGENIC MOUSE; TUMOR XENOGRAFT;

ANIMALS; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; OLIGONUCLEOTIDES, ANTISENSE; POLYMERS; RNA, SMALL INTERFERING;

EID: 60749099046     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.09.024     Document Type: Review

References (120)

1. Stephenson M.L., and Zamecnik P.C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. USA 75 1 (1978) 285-288
2. Grimm D., and Kay M.A. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?. J. Clin. Invest. 117 12 (2007) 3633-3641
3. Sands H., et al. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45 5 (1994) 932-943
4. Agrawal S., et al. Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28 1 (1995) 7-16
5. Toub N., et al. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomed. Pharmacother. 60 9 (2006) 607-620
6. Putnam D., and Doody A. RNA-interference effectors and their delivery. Crit. Rev. Ther. Drug Carrier Syst. 23 2 (2006) 137-164
7. Pan W.H., and Clawson G.A. Antisense applications for biological control. J. Cell. Biochem. 98 1 (2006) 14-35
8. Suri S.S., Fenniri H., and Singh B. Nanotechnology-based drug delivery systems. J. Occup. Med. Toxicol. 2 (2007) 16
9. Paterson B.M., Roberts B.E., and Kuff E.L. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc. Natl. Acad. Sci. USA 74 10 (1977) 4370-4374
10. Zamecnik P.C., and Stephenson M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific ligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 75 1 (1978) 280-284
11. Coppelli F.M., and Grandis J.R. Oligonucleotides as anticancer agents: from the benchside to the clinic and beyond. Curr. Pharm. Des. 11 22 (2005) 2825-2840
12. Dash P., et al. Selective elimination of mRNAs in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity. Proc. Natl. Acad. Sci. USA 84 22 (1987) 7896-7900
13. Fakler B., et al. Short antisense oligonucleotide-mediated inhibition is strongly dependent on oligo length and concentration but almost independent of location of the target sequence. J. Biol. Chem. 269 23 (1994) 16187-16194
14. Augustine K. Antisense approaches for investigating mechanisms of abnormal development. Mutat. Res. 396 1-2 (1997) 175-193
15. Minshull J., and Hunt T. The use of single-stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations. Nucleic Acids Res. 14 16 (1986) 6433-6451
16. Donis-Keller H. Site specific enzymatic cleavage of RNA. Nucleic Acids Res. 7 1 (1979) 179-192
17. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270 8 (2003) 1628-1644
18. Bhindi R., et al. Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am. J. Pathol. 171 4 (2007) 1079-1088
19. Elbashir S.M., et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 6836 (2001) 494-498
20. Elbashir S.M., Lendeckel W., and Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15 2 (2001) 188-200
21. Zamore P.D., et al. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101 1 (2000) 25-33
22. Tolia N.H., and Joshua-Tor L. Slicer and the argonautes. Nat. Chem. Biol. 3 1 (2007) 36-43
23. Hutvagner G., and Simard M.J. Argonaute proteins: key players in RNA silencing. Nat. Rev. Mol. Cell. Biol. 9 1 (2008) 22-32
24. Collins R.E., and Cheng X. Structural and biochemical advances in mammalian RNAi. J. Cell. Biochem. 99 5 (2006) 1251-1266
25. Collins R.E., and Cheng X. Structural domains in RNAi. FEBS Lett. 579 26 (2005) 5841-5849
26. Kim D.H., and Rossi J.J. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8 3 (2007) 173-184
27. Preall JB., and Sontheimer E.J. RNAi: RISC gets loaded. Cell 123 4 (2005) 543-545
28. Manche L., et al. Interactions between double-stranded RNA regulators and the protein kinase DAI. Mol. Cell. Biol. 12 11 (1992) 5238-5248
29. Sen G.C., and Sarkar S.N. The interferon-stimulated genes: targets of direct signaling by interferons, double-stranded RNA, and viruses. Curr. Top. Microbiol. Immunol. 316 (2007) 233-250
30. Farrell L.L., et al. A comparison of the effectiveness of cationic polymers poly-l-lysine (PLL) and polyethylenimine (PEI) for non-viral delivery of plasmid DNA to bone marrow stromal cells (BMSC). Eur. J. Pharm. Biopharm. 65 3 (2007) 388-397
31. Koping-Hoggard M., et al. Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther. 8 14 (2001) 1108-1121
32. Boussif O., et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA 92 16 (1995) 7297-7301
33. Remy-Kristensen A., et al. Role of endocytosis in the transfection of L929 fibroblasts by polyethylenimine/DNA complexes. Biochim. Biophys. Acta 1514 1 (2001) 21-32
34. Akinc A., et al. Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J. Gene Med. 7 5 (2005) 657-663
35. Grzelinski M., et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther. 17 7 (2006) 751-766
36. Schiffelers R.M., et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32 19 (2004) e149
37. Kircheis R., Wightman L., and Wagner E. Design and gene delivery activity of modified polyethylenimines. Adv. Drug Deliv. Rev. 53 3 (2001) 341-358
38. Nimesh S., et al. Polyethylenimine nanoparticles as efficient transfecting agents for mammalian cells. J. Control. Release 110 2 (2006) 457-468
39. Swami A., et al. Imidazolyl-PEI modified nanoparticles for enhanced gene delivery. Int. J. Pharm. 335 1-2 (2007) 180-192
40. Nimesh S., et al. Influence of acyl chain length on transfection mediated by acylated PEI nanoparticles. Int. J. Pharm. 337 1-2 (2007) 265-274
41. Shim M.S., and Kwon Y.J. Controlled delivery of plasmid DNA and siRNA to intracellular targets using ketalized polyethylenimine. Biomacromolecules 9 2 (2008) 444-455
42. Swami A., et al. A unique and highly efficient non-viral DNA/siRNA delivery system based on PEI-bisepoxide nanoparticles. Biochem. Biophys. Res. Commun. 362 4 (2007) 835-841
43. Leonetti J.P., et al. Antiviral activity of conjugates between poly(l-lysine) and synthetic oligodeoxyribonucleotides. Gene 72 1-2 (1988) 323-332
44. Mahato R., et al. Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(l-lysine). Biochem. Pharmacol. 53 6 (1997) 887-895
45. Howard K.A., et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 14 4 (2006) 476-484
46. Katas H., and Alpar H.O. Development and characterisation of chitosan nanoparticles for siRNA delivery. J. Control. Release 115 2 (2006) 216-225
47. Harada A., Togawa H., and Kataoka K. Physicochemical properties and nuclease resistance of antisense-oligodeoxynucleotides entrapped in the core of polyion complex micelles composed of poly(ethylene glycol)-poly(l-lysine) block copolymers. Eur. J. Pharm. Sci. 13 1 (2001) 35-42
48. Read M.L., et al. Physicochemical and biological characterisation of an antisense oligonucleotide targeted against the bcl-2 mRNA complexed with cationic-hydrophilic copolymers. Eur. J. Pharm. Sci. 10 3 (2000) 169-177
49. Vinogradov S.V., Bronich T.K., and Kabanov A.V. Self-assembly of polyamine-poly(ethylene glycol) copolymers with phosphorothioate oligonucleotides. Bioconjug. Chem. 9 6 (1998) 805-812
50. Sato A., et al. Polymer brush-stabilized polyplex for a siRNA carrier with long circulatory half-life. J. Control. Release 122 3 (2007) 209-216
51. Valeeva Y.K., et al. Block copolymers of Pluronics and poly-(2-dimethylamino+ethyl methacrylate) for delivery of oligonucleotides into tumor cells. J. Drug Deliv. Sci. Technol. 16 4 (2006) 245-251
52. Zhang L., et al. Shell-cross-linked micelles containing cationic polymers synthesized via the RAFT process: toward a more biocompatible gene delivery system. Biomacromolecules 8 9 (2007) 2890-2901
53. Hadara A., and Kataoka K. Formation of polyion complex micelles in an aqueous milieu from a pair of oppositely-charged block copolymers with poly(ethylene glycol) segments. Macromolecules 28 (1995) 5294-5299
54. Mao S., et al. Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/SiRNA polyplexes. Bioconjug. Chem. 17 5 (2006) 1209-1218
55. Bartlett D.W., and Davis M.E. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug. Chem. 18 2 (2007) 456-468
56. Cook S.E., et al. Galactosylated polyethylenimine-graft-poly(vinyl pyrrolidone) as a hepatocyte-targeting gene carrier. J. Control. Release 105 1-2 (2005) 151-163
57. Kim S.H., et al. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control. Release 116 2 (2006) 123-129
58. Jeong J.H., Kim S.W., and Park T.G. A new antisense oligonucleotide delivery system based on self-assembled ODN-PEG hybrid conjugate micelles. J. Control. Release 93 2 (2003) 183-191
59. Lee S.H., Kim S.H., and Park T.G. Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide. Biochem. Biophys. Res. Commun. 357 2 (2007) 511-516
60. Oishi M., et al. Supramolecular assemblies for the cytoplasmic delivery of antisense oligodeoxynucleotide: polyion complex (PIC) micelles based on poly(ethylene glycol)-SS-oligodeoxynucleotide conjugate. Biomacromolecules 6 5 (2005) 2449-2454
61. Oishi M., et al. pH-responsive oligodeoxynucleotide (ODN)-poly(ethylene glycol) conjugate through acid-labile beta-thiopropionate linkage: preparation and polyion complex micelle formation. Biomacromolecules 4 5 (2003) 1426-1432
62. Jeong J.H., Kim S.W., and Park T.G. Novel intracellular delivery system of antisense oligonucleotide by self-assembled hybrid micelles composed of DNA/PEG conjugate and cationic fusogenic peptide. Bioconjug. Chem. 14 2 (2003) 473-479
63. Kakizawa Y., Harada A., and Kataoka K. Glutathione-sensitive stabilization of block copolymer micelles composed of antisense DNA and thiolated poly(ethylene glycol)-block-poly(l-lysine): a potential carrier for systemic delivery of antisense DNA. Biomacromolecules 2 2 (2001) 491-497
64. Choi S.H., Lee S.H., and Park T.G. Temperature-sensitive pluronic/poly(ethylenimine) nanocapsules for thermally triggered disruption of intracellular endosomal compartment. Biomacromolecules 7 6 (2006) 1864-1870
65. Lee S.H., et al. Thermally sensitive cationic polymer nanocapsules for specific cytosolic delivery and efficient gene silencing of siRNA: swelling induced physical disruption of endosome by cold shock. J. Control. Release 125 1 (2008) 25-32
66. Vauthier C., Labarre D., and Ponchel G. Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery. J. Drug Target. 15 10 (2007) 641-663
67. Chavany C., et al. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharm. Res. 9 4 (1992) 441-449
68. Lambert G., et al. Effect of polyisobutylcyanoacrylate nanoparticles and lipofectin loaded with oligonucleotides on cell viability and PKC alpha neosynthesis in HepG2 cells. Biochimie 80 12 (1998) 969-976
69. Chauvierre C., et al. Novel polysaccharide-decorated poly(isobutyl cyanoacrylate) nanoparticles. Pharm. Res. 20 11 (2003) 1786-1793
70. Bertholon I., et al. Characterization of dextran-poly(isobutylcyanoacrylate) copolymers obtained by redox radical and anionic emulsion polymerization. Macromolecules 39 10 (2006) 3559-3567
71. Couvreur P., et al. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J. Pharm. Pharmacol. 31 5 (1979) 331-332
72. Chauvierre C., et al. Radical emulsion polymerization of alkylcyanoacrylates initiated by the redox system dextran-cerium(iv) under acidic aqueous conditions. Macromolecules 36 16 (2003) 6018-6027
73. Isomaa B., and Ekman K. Embryotoxic and teratogenic effects of CTAB, a cationic surfactant, in the mouse. Food Cosmet. Toxicol. 13 3 (1975) 331-334
74. Isomaa B., Reuter J., and Djupsund B.M. The subacute and chronic toxicity of cetyltrimethylammonium bromide (CTAB), a cationic surfactant, in the rat. Arch. Toxicol. 35 2 (1976) 91-96
75. Vinsova J., and Vavrikova E. Recent advances in drugs and prodrugs design of chitosan. Curr. Pharm. Des. 14 13 (2008) 1311-1326
76. Varshosaz J. The promise of chitosan microspheres in drug delivery systems. Expert Opin. Drug Deliv. 4 3 (2007) 263-273
77. Yang S.C., et al. Formation of positively charged poly(butyl cyanoacrylate) nanoparticles stabilized with chitosan. Colloids Polym. Sci. 278 4 (2000) 285-292
78. Bertholon I., Vauthier C., and Labarre D. Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology length, and type of polysaccharide. Pharm Res. 23 6 (2006) 1313-1323
79. Maksimenko A., et al. In vivo potentialities of EWS-Fli-1 targeted antisense oligonucleotides-nanospheres complexes. Ann. NY Acad. Sci. 1058 (2005) 52-61
80. Maksimenko A., et al. Therapeutic potentialities of EWS-Fli-1 mRNA-targeted vectorized antisense oligonucleotides. Ann. NY Acad. Sci. 1002 (2003) 72-77
81. Pille JY., et al. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum. Gene Ther. 17 10 (2006) 1019-1026
82. de Martimprey H., et al. siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Res. 36 1 (2008) e2
83. Nafee N., et al. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine 3 3 (2007) 173-183
84. Zwiorek K., et al. Gelatin nanoparticles as a new and simple gene delivery system. J. Pharm. Pharm. Sci. 7 4 (2005) 22-28
85. Zillies J., and Coester C. Evaluating gelatin based nanoparticles as a carrier system for double stranded oligonucleotides. J. Pharm. Pharm. Sci. 7 4 (2005) 17-21
86. Langer K., et al. Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid. Eur. J. Pharm. Biopharm. 49 3 (2000) 303-307
87. Coester C., et al. Preparation of avidin-labelled gelatin nanoparticles as carriers for biotinylated peptide nucleic acid (PNA). Int. J. Pharm. 196 2 (2000) 147-149
88. Fraunhofer W., Winter G., and Coester C. Asymmetrical flow field-flow fractionation and multiangle light scattering for analysis of gelatin nanoparticle drug carrier systems. Anal. Chem. 76 7 (2004) 1909-1920
89. Lambert G., et al. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm. Res. 17 6 (2000) 707-714
90. Lambert G., et al. EWS fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. Biochem. Biophys. Res. Commun. 279 2 (2000) 401-406
91. Toub N., et al. Cellular fate of oligonucleotides when delivered by nanocapsules of poly(isobutylcyanoacrylate). J. Control. Release 106 1-2 (2005) 209-213
92. Toub N., et al. Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm Res. 23 5 (2006) 892-900
93. Hillaireau H., et al. Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages. J. Control. Release 116 3 (2006) 346-352
94. Hillaireau H., et al. Encapsulation of mono- and oligo-nucleotides into aqueous-core nanocapsules in presence of various water-soluble polymers. Int. J. Pharm. 331 2 (2007) 148-152
95. Zheng Y., et al. l-lactic-co-glycolic acid) and an ornithine-histidine peptide as carriers of oligodeoxynucleotide for delivery into primary dendritic cells. J. Biomater. Sci. Polym. Ed. 17 12 (2006) 1389-1403
96. Cohen-Sacks H., et al. Novel PDGFbetaR antisense encapsulated in polymeric nanospheres for the treatment of restenosis. Gene Ther. 9 23 (2002) 1607-1616
97. Wee S., and Gombotz W.R. Protein release from alginate matrices. Adv. Drug Deliv. Rev. 31 3 (1998) 267-285
98. Rajaonarivony M., et al. Development of a new drug carrier made from alginate. J. Pharm. Sci. 82 9 (1993) 912-917
99. Aynié I., et al. Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 9 3 (1999) 301-312
100. Gonzalez Ferreiro M., et al. Characterization of alginate/poly-l-lysine particles as antisense oligonucleotide carriers. Int. J. Pharm. 239 1-2 (2002) 47-59
101. Douglas K.L., and Tabrizian M. Effect of experimental parameters on the formation of alginate-chitosan nanoparticles and evaluation of their potential application as DNA carrier. J. Biomater. Sci. Polym. Ed. 16 1 (2005) 43-56
102. Akhtar S., and Benter I.F. Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 117 12 (2007) 3623-3632
103. Nakada Y., et al. Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice. Pharm. Res. 13 1 (1996) 38-43
104. Peetla C., and Labhasetwar V. Biophysical characterization of nanoparticle-endothelial model cell membrane interactions. Mol. Pharm. 5 3 (2008) 418-429
105. Chumakova O.V., et al. Composition of PLGA and PEI/DNA nanoparticles improves ultrasound-mediated gene delivery in solid tumors in vivo. Cancer Lett. 261 2 (2008) 215-225
106. Jones R.A., Poniris M.H., and Wilson M.R. pDMAEMA is internalised by endocytosis but does not physically disrupt endosomes. J. Control. Release 96 3 (2004) 379-391
107. Liu X., et al. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 28 6 (2007) 1280-1288
108. Gao S., et al. Targeting delivery of oligonucleotide and plasmid DNA to hepatocyte via galactosylated chitosan vector. Eur. J. Pharm. Biopharm. 60 3 (2005) 327-334
109. Kim S.T., and Kim C.K. Water-soluble chitosan-based antisense oligodeoxynucleotide of interleukin-5 for treatment of allergic rhinitis. Biomaterials 28 22 (2007) 3360-3368
110. Jahraus A., et al. Evidence for retrograde traffic between terminal lysosomes and the prelysosomal/late endosome compartment. J. Cell Sci. 107 1 (1994) 145-157
111. Urban-Klein B., et al. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12 5 (2005) 461-466
112. Couvreur P., and Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 23 7 (2006) 1417-1450
113. Maeda H., Seymour L.W., and Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug. Chem. 3 5 (1992) 351-362
114. Iyer A.K., et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11 17-18 (2006) 812-818
115. de Wolf H.K., et al. Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration. Int. J. Pharm. 331 (2007) 167-175
116. Hu-Lieskovan S., et al. Sequence-specific knockdown of EWS-Fli1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65 19 (2005) 8984-8992
117. Bartlett D.W., et al. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. USA 104 39 (2007) 15549-15554
118. Bartlett D.W., and Davis M.E. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol. Bioeng. 99 4 (2008) 975-985
119. Heidel J.D., et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. USA 104 14 (2007) 5715-5721
120. Schwab G., et al. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. Acad. Sci. USA 91 22 (1994) 10460-10464